484 related articles for article (PubMed ID: 34862664)
1. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
3. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system.
Tsuyuki Y; Ishikawa E; Kohno K; Shimada K; Ohka F; Suzuki Y; Mabuchi S; Satou A; Takahara T; Kato S; Miyagi S; Ozawa H; Kawano T; Takagi Y; Hiraga J; Wakabayashi T; Nakamura S
Neuropathology; 2021 Apr; 41(2):99-108. PubMed ID: 33269495
[TBL] [Abstract][Full Text] [Related]
4. PD-L1
Pollari M; Brück O; Pellinen T; Vähämurto P; Karjalainen-Lindsberg ML; Mannisto S; Kallioniemi O; Kellokumpu-Lehtinen PL; Mustjoki S; Leivonen SK; Leppä S
Haematologica; 2018 Nov; 103(11):1908-1914. PubMed ID: 30026337
[TBL] [Abstract][Full Text] [Related]
5. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
Marcelis L; Antoranz A; Delsupehe AM; Biesemans P; Ferreiro JF; Debackere K; Vandenberghe P; Verhoef G; Gheysens O; Cattoretti G; Bosisio FM; Sagaert X; Dierickx D; Tousseyn T
Cancer Immunol Immunother; 2020 Sep; 69(9):1751-1766. PubMed ID: 32335702
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
7. Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system.
Liu B; Yan S; Li S; Zhang Q; Yang M; Yang L; Ma J; Li X
Pathol Res Pract; 2022 Nov; 239():154008. PubMed ID: 36183436
[TBL] [Abstract][Full Text] [Related]
8. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.
Wang J; Gao K; Lei W; Dong L; Xuan Q; Feng M; Wang J; Ye X; Jin T; Zhang Z; Zhang Q
Oncotarget; 2017 Jan; 8(3):5414-5425. PubMed ID: 28036275
[TBL] [Abstract][Full Text] [Related]
10. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
[TBL] [Abstract][Full Text] [Related]
13. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
14. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Shi Y; Deng L; Song Y; Lin D; Lai Y; Zhou L; Yang L; Li X
Int J Hematol; 2018 Sep; 108(3):254-266. PubMed ID: 29748856
[TBL] [Abstract][Full Text] [Related]
15. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
[TBL] [Abstract][Full Text] [Related]
16. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
17. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
19. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
20. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]